[go: up one dir, main page]

NO20073758L - 2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl-piperidines used as CGRP antagonists - Google Patents

2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl-piperidines used as CGRP antagonists

Info

Publication number
NO20073758L
NO20073758L NO20073758A NO20073758A NO20073758L NO 20073758 L NO20073758 L NO 20073758L NO 20073758 A NO20073758 A NO 20073758A NO 20073758 A NO20073758 A NO 20073758A NO 20073758 L NO20073758 L NO 20073758L
Authority
NO
Norway
Prior art keywords
benzodiazepin
tetrahydro
oxo
cgrp antagonists
salts
Prior art date
Application number
NO20073758A
Other languages
Norwegian (no)
Inventor
Henri Nico Doods
Klaus Rudolf
Stephan Georg Mueller
Dirk Stenkamp
Kirsten Arndt
Alexander Dreyer
Gerhard Schaenzle
Marco Santagostino
Fabio Paleari
Philipp Lustenberger
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2005/003094 external-priority patent/WO2005092880A1/en
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of NO20073758L publication Critical patent/NO20073758L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Addiction (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)

Abstract

Det beskrives nye CGRP-antagonister med den generelle Formel (I) hvor B, R1 og R2 er som definert i krav 1, deres tautomerer, deres isomerer, deres diastereomerer, deres enantiomerer, deres hydrater, deres blandinger og deres salter, samt hydratene av saltene, særlig deres fysiologisk akseptable salter med uorganiske eller organiske syrer eller baser, medikamenter inneholdende disse forbindelsene, deres anvendelse og fremgangsmåte for deres fremstilling. ?? ?? ?? ?? 1New CGRP antagonists of general Formula (I) are disclosed wherein B, R1 and R2 are as defined in claim 1, their tautomers, their isomers, their diastereomers, their enantiomers, their hydrates, their mixtures and their salts, as well as the hydrates of the salts, especially their physiologically acceptable salts with inorganic or organic acids or bases, drugs containing these compounds, their use and process for their preparation. ?? ?? ?? ?? 1

NO20073758A 2005-03-23 2007-07-19 2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl-piperidines used as CGRP antagonists NO20073758L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2005/003094 WO2005092880A1 (en) 2004-03-29 2005-03-23 Selected cgrp antagonists, methods for the production thereof and their use as medicaments
PCT/EP2006/002557 WO2006100026A1 (en) 2005-03-23 2006-03-21 2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl-piperidines used as cgrp antagonists

Publications (1)

Publication Number Publication Date
NO20073758L true NO20073758L (en) 2007-10-19

Family

ID=36406232

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20073758A NO20073758L (en) 2005-03-23 2007-07-19 2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl-piperidines used as CGRP antagonists

Country Status (19)

Country Link
EP (2) EP1992349B8 (en)
JP (1) JP4210322B2 (en)
KR (1) KR20070113317A (en)
CN (2) CN101146799A (en)
AU (1) AU2006226544A1 (en)
CA (1) CA2600189A1 (en)
DE (1) DE502006002066D1 (en)
DK (1) DK1863791T5 (en)
EA (1) EA012590B1 (en)
ES (1) ES2317512T3 (en)
HR (1) HRP20090011T3 (en)
MY (1) MY144635A (en)
NO (1) NO20073758L (en)
PL (1) PL1863791T3 (en)
PT (1) PT1863791E (en)
RS (1) RS50722B (en)
SI (1) SI1863791T1 (en)
WO (1) WO2006100026A1 (en)
ZA (1) ZA200705852B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10250082A1 (en) 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Selected CGRP antagonists, process for their preparation and their use as pharmaceuticals
DE102004015723A1 (en) * 2004-03-29 2005-10-20 Boehringer Ingelheim Pharma Selected CGRP antagonists, process for their preparation and their use as pharmaceuticals
US7696195B2 (en) 2004-04-22 2010-04-13 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
EP1770086A1 (en) * 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG Selected CGRP antagonists, process for their preparation as well as their use as medicaments
CA2654048A1 (en) * 2006-06-08 2007-12-13 Boehringer Ingelheim International Gmbh Treatment of gastrointestinal disorders with cgrp antagonists

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10250082A1 (en) * 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Selected CGRP antagonists, process for their preparation and their use as pharmaceuticals
DE10250080A1 (en) * 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Selected CGRP antagonists, process for their preparation and their use as pharmaceuticals
EP1644332A1 (en) 2003-07-03 2006-04-12 Poseidon Pharmaceuticals A/S Diarylmethyl derivatives as potassium channel modulators
TW200533398A (en) 2004-03-29 2005-10-16 Bristol Myers Squibb Co Novel therapeutic agents for the treatment of migraine
EP1619187A1 (en) 2004-07-23 2006-01-25 Boehringer Ingelheim Pharma GmbH & Co. KG Process for the preparation of 3-(4-piperidinyl)- 2,3,4,5-tetrahydro-1,3-benzodiazepin-2(1H)-on

Also Published As

Publication number Publication date
KR20070113317A (en) 2007-11-28
EP1992349A1 (en) 2008-11-19
DK1863791T3 (en) 2009-02-16
PT1863791E (en) 2008-12-15
JP2008533083A (en) 2008-08-21
EA012590B1 (en) 2009-10-30
EA200701843A1 (en) 2008-02-28
PL1863791T3 (en) 2009-04-30
HRP20090011T3 (en) 2009-02-28
EP1863791B1 (en) 2008-11-12
EP1992349B1 (en) 2013-07-31
MY144635A (en) 2011-10-14
EP1992349B8 (en) 2013-10-09
RS50722B (en) 2010-08-31
JP4210322B2 (en) 2009-01-14
CA2600189A1 (en) 2006-09-28
ZA200705852B (en) 2009-12-30
CN101146790A (en) 2008-03-19
AU2006226544A1 (en) 2006-09-28
DK1863791T5 (en) 2010-10-04
SI1863791T1 (en) 2009-04-30
WO2006100026A8 (en) 2007-02-08
EP1863791A1 (en) 2007-12-12
ES2317512T3 (en) 2009-04-16
WO2006100026A1 (en) 2006-09-28
DE502006002066D1 (en) 2008-12-24
CN101146799A (en) 2008-03-19

Similar Documents

Publication Publication Date Title
NO20064166L (en) Selected CGRP antagonists, their preparation and their use as medicaments
NO20076680L (en) Selected CGRP antagonists, methods for their preparation and their use as drugs
NO20052493L (en) Selected CGRP antagonists, processes for their preparation and their use as pharmaceutical compositions.
NO20052496L (en) Selected CGRP antagonists, methods for their preparation and use thereof as drugs.
NO20091893L (en) New 1,4-benzothiepine-1,1-dioxide derivatives substituted with benzyl groups, processes for the preparation of medicaments containing the compounds and their use.
WO2009065919A3 (en) Organic compounds
WO2009065920A3 (en) Compounds
NO20085066L (en) 4,5-diphenyl-pyrimidinyl-amino-substituted carboxylic acids, process for their preparation and use thereof as medicaments
NO20070176L (en) New fluorine glycoside derivatives of pyrazoles, drugs containing these compounds and their use
NO20053794L (en) N- (1-benzyl-2-oxo-2- (1-piperazinyl) ethyl) -1-piperidinecarboxamide derivatives and related compounds use as CGRP antagonists for the treatment of headaches.
TW200606151A (en) Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
NO20074391L (en) CIS-2,4,5-triaryl imidazolines and their use as anti-cancer drugs
ATE402174T1 (en) IMIDAZOPYRIDINE DERIVATIVES AS KINASE INHIBITORS
NO20076695L (en) New MCHR1 antagonists and their use in the treatment of MCHR1-mediated conditions and disorders
NO20070532L (en) Substituted 2-alkyl quinazolinone derivatives as PARP inhibitors
NO20064201L (en) Glucopyranosyl substituted benzene derivatives, drugs containing such compounds, their use and preparation
NO20023161L (en) Substituted piperidines, drugs containing these compounds and processes for their preparation
EA201000612A1 (en) ANTAGONISTS CGRP-PEPTIDES
WO2007036532A3 (en) Selected cgrp antagonists, methods for the production thereof and their use as medicaments
NO20080033L (en) Quinoline derivatives as NK3 antagonists
TW200603799A (en) Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
WO2009034029A3 (en) 1-substituted 4-heterocyclylpiperidines for use as cgrp antagonists
NO20073758L (en) 2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl-piperidines used as CGRP antagonists
NO20060146L (en) Benzimidazole derivatives, compositions containing them, their preparation and their use
ATE476431T1 (en) PIPERIDINE AND AZETIDINE DERIVATIVES AS GLYT1 INHIBITORS

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application